Form 4: Nkarta Director Michael Dybbs Granted 46,000 Stock Options

Nkarta, Inc. Director Michael Dybbs was granted 46,000 stock options with an exercise price of $1.83, aligning his interests with the company's long-term performance.

Summary

• Michael Dybbs, a Director of Nkarta, Inc. (NKTX), was granted 46,000 stock options.
• The transaction date for the option grant was June 5, 2025.
• The exercise price for these stock options is $1.83 per share.
• The options are set to vest 100% on the earlier of June 5, 2026, or the day immediately preceding the first annual meeting of the Issuer's stockholders after the grant date.
• Accelerated vesting will occur upon a 'change in control' of Nkarta, Inc. or upon Mr. Dybbs' separation from service due to death or disability.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Michael Dybbs beneficially owns 46,000 derivative securities (stock options) directly.
• The filing includes a Power of Attorney, executed on June 8, 2025, authorizing specific individuals to file SEC reports on behalf of Michael Dybbs.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it is a routine compensation event and not indicative of significant new operational or financial developments.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued commitment and performance from the director.

Future Outlook

The vesting schedule of the stock options indicates a future commitment from the director, with full vesting expected by June 5, 2026, or the next annual meeting, aligning the director's long-term incentives with the company's performance.

Industry Context

The grant of stock options is a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, aiming to attract and retain talent while aligning their financial interests with company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice for executive and board compensation across various industries, including biotechnology, to incentivize long-term performance and align interests with shareholders.
• The vesting schedule, which includes both a time-based component and accelerated vesting upon specific events like a change in control, is typical for such equity awards.

Related Party Transactions

• The grant of 46,000 stock options to Michael Dybbs, a Director of Nkarta, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest according to the specified schedule, either on June 5, 2026, or prior to the next annual meeting of stockholders.
• The options will remain exercisable until their expiration date of June 4, 2035, assuming they are vested and outstanding.

Key Dates

Recommendation

Keywords

Nkarta, NKTX, Stock Option, Insider Transaction, Director Compensation, Beneficial Ownership, SEC Form 4, Equity Compensation